Evercore ISI Boosts Intuitive Surgical (NASDAQ:ISRG) Price Target to $490.00

Intuitive Surgical (NASDAQ:ISRG) had its price target boosted by Evercore ISI from $475.00 to $490.00 in a research report report published on Friday, MarketBeat reports. They currently have an in-line rating on the medical equipment provider’s stock.

Several other research firms have also recently commented on ISRG. Piper Sandler reissued an “overweight” rating and set a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research note on Friday. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research report on Friday. Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a report on Friday. Truist Financial boosted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $521.15 on Friday. Intuitive Surgical has a one year low of $254.85 and a one year high of $523.34. The firm has a 50 day simple moving average of $483.85 and a 200-day simple moving average of $438.56. The firm has a market cap of $184.85 billion, a price-to-earnings ratio of 94.07, a PEG ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.18 EPS. Equities analysts predict that Intuitive Surgical will post 5.22 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 1,413 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total transaction of $619,741.80. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,414,931.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Myriam Curet sold 2,818 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at $136,522.74. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirador Capital Partners LP lifted its holdings in shares of Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 50 shares during the period. Advisors Asset Management Inc. raised its position in Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after buying an additional 1,129 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after acquiring an additional 76,649 shares during the period. Brookstone Capital Management lifted its stake in shares of Intuitive Surgical by 22.4% in the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock worth $5,340,000 after acquiring an additional 2,289 shares during the period. Finally, M&G Plc boosted its holdings in shares of Intuitive Surgical by 53.5% in the second quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after acquiring an additional 1,766 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.